? ? Delayed myeloid engraftment after umbilical cord blood transplantation (UCBT), often associated with increased early transplant related morbidity and mortality, remains the primary obstacle for the successful use of cord blood as an alternative source of stem cells for allogeneic transplantation and novel strategies are required to overcome this problem. Although the delayed engraftment following UCBT has been thought to result from inadequate stem cell numbers in a cord blood graft, attempts to increase the stem cell numbers available by ex vivo cytokine-mediated expansion has not improved time to engraftment. Similarly, infusion of multiple cord blood units, while possibly effective in increasing the overall incidence of engraftment, has not overcome the problem of the slow pace of hematopoietic recovery. Our laboratory has developed novel methods for enhancing the repopulating capacity of cord blood progenitors, using the Notch ligand, Deltal. With support from this R24 grant, we have developed the required clinical grade reagents and methodology for the ex vivo expansion of cord blood progenitors, thereby establishing a potential resource to provide these reagents and methods to improve the outcome following cord blood transplantation. Preclinical data has demonstrated not only the ability to expand ex vivo progenitor cells with enhanced repopulating ability, but also indicates that the expanded cells may lead to more rapid engraftment, the major disadvantage after undergoing UCBT. Thus, based on the encouraging data generated during the preclinical development phase, we are now ready to establish the safety and toxicity of our approach in a phase I clinical trial, and then to provide this technology as a resource for multi-institutional phase II and III trials to test efficacy. Specifically, we propose to determine the safety and toxicity associated with infusion of ex vivo expanded cord blood cells to augment conventional umbilical cord blood transplantation in a phase I clinical trial. These studies will also address ancillary aims of estimating the kinetics and durability of hematopoietic reconstitution of the ex vivo expanded cord blood cells (Aim IA) and estimating the kinetics of immune cell reconstitution (Aim IB). ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Resource-Related Research Projects (R24)
Project #
5R24HL074445-05
Application #
7274330
Study Section
Special Emphasis Panel (ZHL1-CSR-R (M3))
Program Officer
Mondoro, Traci
Project Start
2003-07-01
Project End
2011-06-30
Budget Start
2007-07-01
Budget End
2011-06-30
Support Year
5
Fiscal Year
2007
Total Cost
$1,004,240
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Salit, Rachel B; Milano, Filippo; Delaney, Colleen (2016) Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation. Biol Blood Marrow Transplant 22:339-343
Newell, L F; Flowers, M E D; Gooley, T A et al. (2013) Characteristics of chronic GVHD after cord blood transplantation. Bone Marrow Transplant 48:1285-90
Milano, Filippo; Chien, Jason W; Riffkin, Ivy et al. (2012) Stable long-term pulmonary function after myeloablative double cord blood transplant. Biol Blood Marrow Transplant 18:309-13
Milano, Filippo; Pergam, Steven A; Xie, Hu et al. (2011) Intensive strategy to prevent CMV disease in seropositive umbilical cord blood transplant recipients. Blood 118:5689-96
Dahlberg, Ann; Delaney, Colleen; Bernstein, Irwin D (2011) Ex vivo expansion of human hematopoietic stem and progenitor cells. Blood 117:6083-90
Delaney, Colleen; Heimfeld, Shelly; Brashem-Stein, Carolyn et al. (2010) Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 16:232-6
Gutman, Jonathan A; Turtle, Cameron J; Manley, Thomas J et al. (2010) Single-unit dominance after double-unit umbilical cord blood transplantation coincides with a specific CD8+ T-cell response against the nonengrafted unit. Blood 115:757-65
Watts, Korashon L; Delaney, Colleen; Humphries, R Keith et al. (2010) Combination of HOXB4 and Delta-1 ligand improves expansion of cord blood cells. Blood 116:5859-66
Delaney, Colleen; Varnum-Finney, Barbara; Aoyama, Keisuke et al. (2005) Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 106:2693-9